Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib

计划入组 53 人 · 首次发布于 2026 年 3 月 20 日

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

计划入组 110 人 · 首次发布于 2024 年 8 月 1 日

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

计划入组 134 人 · 首次发布于 2025 年 6 月 26 日

Oxybenzone(Meijer)

C₁₄H₁₂O₃

BE-3-3-3-3

Indole-3-carbinol

C₉H₉NO

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

Evexta Bio and Roche Ink Clinical Collaboration to Evaluate Rupitasertib Plus Giredestrant in ESR1-Mutated Metastatic Breast Cancer

Truqap plus Abiraterone and ADT Improves rPFS in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

Truqap Plus Abiraterone Shows Promise in PTEN-Deficient Metastatic Prostate Cancer